{"id":"NCT02165826","sponsor":"AstraZeneca","briefTitle":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","officialTitle":"A Multicenter, Randomized, Double-blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-titration Regimen in COPD, Including an Open-label Down-titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg Roflumilast Once Daily in Subjects Not Tolerating 500 μg Roflumilast Once-daily","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05-01","primaryCompletion":"2015-09-01","completion":"2015-09-01","firstPosted":"2014-06-18","resultsPosted":"2017-03-14","lastUpdate":"2017-04-20"},"enrollment":1323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Roflumilast","otherNames":["Daxas, Daliresp, Libertek"]},{"type":"DRUG","name":"Roflumilast Placebo","otherNames":[]},{"type":"DRUG","name":"Standard of Care COPD Treatment","otherNames":[]}],"arms":[{"label":"Roflumilast 500 μg once daily","type":"EXPERIMENTAL"},{"label":"Roflumilast 500 μg every other day","type":"EXPERIMENTAL"},{"label":"Roflumilast 250 μg once daily","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week main period, and to evaluate if participants who do not tolerate roflumilast 500 μg OD have a drug exposure with 250 μg roflumilast OD similar to that observed in other participants with the 500 μg OD dose.","primaryOutcome":{"measure":"Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason","timeFrame":"Baseline to Week 12 (Main Period)","effectByArm":[{"arm":"Roflumilast 250 μg OD Then 500 μg OD","deltaMin":18.4,"sd":null},{"arm":"Roflumilast 500 μg EOD Then 500 μg OD","deltaMin":20.1,"sd":null},{"arm":"Roflumilast 500 μg OD","deltaMin":24.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.017"},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":"0.114"},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["Slovakia"]},"refs":{"pmids":["29797235"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":441},"commonTop":["Diarrhoea","Headache","Decreased appetite","Insomnia","Nausea"]}}